JUNO AND CELGENE release additional data from transcend trial of JCAR017 in patients with relapsed or refractory aggressive B-Cell non-hodgkin lymphoma.
As of the October 9, 2017 data cutoff date
Efficacy
—74% (14/19) ORR and 68% (13/19) CR rate at 3 months and 50% (7/14) CR at 6 months in core group at dose level 2
—Across doses, 80% (16/20) of core group patients in CR at month 3 remain in response at month 6; 92% (11/12) of core group patients in response at 6 months remain in response
Safety in core group
-1% (1/91) experienced severe CRS and 12% (11/91) experienced severe NT.
-35% (32/91) had any grade CRS and 19% (17/91) had any grade NT.
-60% (55/91) had no CRS or NT of any grade.
As a comparison, below shows the related result as of a data cutoff date of July 7, 2017
Efficacy
-Dose level 2, 3 month overall response rate (ORR) of 80% (12/15) and a 3 month complete response (CR) rate of 73% (11/15) in the core group.
Safety
-1% (1/69) experienced severe CRS and 14% (10/69) experienced severe NT.
-30% (21/69) had any grade CRS and 20% (14/69) had any grade NT.
-64% (44/69) had no CRS or NT.
From the comparison above, we can notice that the efficacy and safety of JCAR017 are maintained even when the number of patients and the treatment period increase.
Alex